SCHEMBL3012928

SCHEMBL3012928

O=S(=O)(c1ccc(Br)cc1)N1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.59
SMN1; SMN2 Q16637 6/20 0.54
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
POLB P06746 1/20 0.50
MAPT P10636 4/20 0.47
USP2 O75604 2/20 0.47
HSD17B10 Q99714 2/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 2/20 0.46
KMT2A Q03164 6/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MEN1 O00255 5/20 0.42
HPGD P15428 2/20 0.42
PKM P14618 1/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 3/20 0.42
MAPK1 P28482 3/20 0.42
NPC1 O15118 1/20 0.41
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006931 0.94 AR (0.64) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3011465 0.90 AR (0.57) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3022480 0.90 SMN1; SMN2 (0.69) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3013101 0.90 AR (0.59) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3011492 0.89 AR (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL2997717 0.88 AR (0.60) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3014225 0.88 AR (0.63) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3006789 0.88 AR (0.57) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3010740 0.87 AR (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL3007723 0.87 MAPT (0.57) ARSMN1; SMN2ALDH1A1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.